New treatment options in PKU and future role of dietary treatment
|
|
- Scarlett Bryant
- 5 years ago
- Views:
Transcription
1 New treatment options in PKU and future role of dietary treatment Michael Staudigl (physician), Katharina Dokoupil (nutritionist), Esther M. Maier (physician, head of department) Dr. von Hauner Children s Hospital, Department of Inborn Errors of Metabolism, University of Munich, Munich, Germany Introduction Phenylalanine hydroxylase (PAH; EC ) catalyzes the hydroxylation of the aromatic amino acid phenylalanine to tyrosine. Mutations in the PAH gene lead to the most common inherited disorder of amino acid metabolism in the European-descended population, namely Phenylketonuria (PKU; OMIM ) (Zschocke, 2003). PAH deficiency leads to an elevation of phenylalanine concentrations in blood resulting in severely impaired cognitive and motor development if untreated. The implementation of newborn screening in the 1960s has helped to identify newborns with PKU within the first days of life and allowed early initiation of treatment to prevent these deleterious effects. For over 60 years, the mainstay of PKU treatment has been a phenylalanine-restricted diet. Yet, with ongoing research, new therapeutic options have emerged. We provide a short overview of current and future treatment options for PKU patients and the future role of dietary treatment. Current Treatment Options Phenylalanine-restricted diet. Until today, a phenylalanine-restricted diet remains the main treatment option for PKU patients. Yet, following a strict diet is burdensome and may hamper compliance. In addition, the nutritional management of PKU has become more complex in order to optimize patients growth, development and diet compliance (Feillet & Agostoni, 2010). Therefore, companies specialized in medicinal foods have made great efforts to develop new products and improve existing products to comply with today s needs. As these products have become more palatable, therapeutic compliance has increased but regular monitoring of blood phenylalanine levels and assessment of nutrient intake and biochemical markers of nutrition remain. Additionally, repeated dietary education aiming to avoid protein malnutrition and other nutrient deficiencies is continuously needed. Large neutral amino-acids (LNAAs). LNAAs inhibit the transport of phenylalanine across the gastrointestinal and the blood brain barrier by competing with the same transporter (Matalon et al.,
2 2 2006). Unfortunately, the effects of LNAAs have been assessed only for a short time and in a limited number of patients using variable dosages and different formulations (Blau, Hennermann, Langenbeck, & Lichter-Konecki, 2011). Evidence to support the efficacy of LNAA supplementation in significantly reducing blood phenylalanine levels in PKU patients is therefore still limited and further research is needed (Strisciuglio & Concolino, 2014). Pharmacological chaperone treatment. In 1999, Kure et al. discovered that pharmacological doses of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4), the natural cofactor of PAH, lead to a reduction in phenylalanine concentrations of patients with PAH deficiency (Kure et al., 1999). Further studies showed, that BH4 reduces blood phenylalanine concentrations and increases enzyme activity and phenylalanine tolerance (Muntau et al., 2002). These findings led to the description of a new clinical phenotype, namely BH4-responsive PAH deficiency. Recent studies have shown, that PKU is a protein misfolding disease with loss-of-function (Gersting et al., 2007), and BH4 acts as a pharmacological chaperone stabilizing misfolded proteins (Gersting et al., 2010)(Lagler et al., 2010). In 2008, Sapropterin-dihydrochloride (KUVAN ) was approved for the treatment of BH4-responsive PAH deficiency in Europe. As PKU is an inborn error of metabolism with high genetic variability, allelic heterogeneity and frequent compound-heterozygosity, prediction of the clinical phenotype leading to individualized treatment decisions is difficult (Danecka et al., 2015). Current studies aim to understand the functional mechanisms underlying the loss-of-function phenotype by analysis of genotype-specific activity landscapes which allow insights into the interplay between the genotype, the metabolic state and pharmacological treatment with BH4 (Danecka et al., 2015; Staudigl et al., 2011). Future Treatment Options In the past years, new alternatives to current treatment strategies have evolved. Glycomacropeptide, enzyme substitution, gene therapy, and hepatocyte transplantation seem to be promising approaches undergoing continuous research. Glycomacropeptide (GMP). GMP occurs naturally in bovine milk within the whey fraction during cheese production (Ney, Blank, & Hansen, 2014). It represents a new dietary treatment option for PKU patients as pure GMP contains no aromatic amino acids, including phenylalanine (Etzel, 2004). In addition, GMP contains up to three times the amount of LNAAs as compared with other dietary proteins (van Calcar & Ney, 2012). In order to provide a complete source of protein, GMP must be supplemented with essential amino acids (van Calcar & Ney, 2012). Studies in PKU mice showed,
3 3 that GMP is suitable to support normal growth and body composition (Solverson et al., 2012). Until today, an increasing number of foods and beverages have been developed using GMP as a protein source with reduced phenylalanine content (van Calcar & Ney, 2012). Currently, a phase 2 study will evaluate the metabolic and nutritional features of a GMP diet in comparison to an amino acid diet in PKU ( NCT ). Enzyme substitution. Phenylalanine ammonia lyase (PAL) is a non-mammalian protein found in plants, yeast, and bacteria. PAL converts phenylalanine to trans-cinnamic acid, a harmless organic acid being rapidly excreted in urine, and insignificant levels of ammonia (Sarkissian et al., 2008). Weekly subcutaneous injection of the polyethylene glycol (PEG)-modified recombinant PAL (ravpal-peg) to Pah enu2 mice led to complete and sustained correction of blood phenylalanine levels (Harding & Blau, 2010). These results led to the initiation of clinical trials of injectable ravpal-peg. Currently, patients are being recruited for an open-label Phase 3 study to evaluate safety and tolerability over a time frame of 36 weeks ( In addition, experiments have been performed with corn-root-derived PAL for a potential oral therapeutic use (López-Villalobos et al., 2014). Gene therapy. PKU has been a target disease for gene therapy for many years (Fang et al., 1994). Different studies have used Adeno-associated hepatocyte-directed viral vectors to correct blood phenylalanine concentrations. Yet, these vectors do not achieve a permanent metabolic correction as continuous hepatocyte regeneration eventually eliminates the vector genomes, thus leading to a loss of PAH expression (Harding & Blau, 2010). Reinjection is ineffective due to antibody-mediated destruction of the vector (Harding & Blau, 2010). More promising results have been demonstrated by intramuscular injection in PKU mice (Ding et al., 2008). Until today, research is continuing, improving hepatocyte- or muscle-directed gene therapy for PAH deficiency. Hepatocyte transplantation. In PKU, liver organ transplantation is not an option. Therefore, repopulation of the liver with wild-type hepatocytes or stem cells has been explored as a potential therapy in both animal models and humans (Harding & Gibson, 2010). Transplantation of wild-type hepatocytes in PKU mice demonstrated a complete correction of blood phenylalanine concentrations in animals with at least 10% liver repopulation (Hamman et al., 2005). As in gene therapy, the major limitation to hepatocyte transplantation is the lack of a selective growth advantage of PAH-expressing cells over native PAH-deficient hepatocytes (Harding & Blau, 2010)(Laconi & Laconi, 2002). Conclusion
4 4 In the past years, promising new therapeutic options for PKU patients have evolved i.e. GMP, enzyme substitution, gene therapy, and hepatocyte transplantation. However, further research and clinical studies are needed to determine the safety and the efficacy of these developing treatment strategies. Until then, the available treatment options for patients with PKU consist of phenylalanine-restricted diet and treatment with KUVAN. The approval of KUVAN for BH4-responsive PAH deficiency has led to an increased quality of life for an increasing number of patients. Yet, these patients still show alterations with respect to a healthy, well balanced diet. They developed special eating habits and preferences in their lifetime leading to deficits in vitamin and mineral intake (Lambruschini et al., 2005). Thus, continuous nutritional follow-up with education, monitoring, and supplementation is needed. For many patients, current and future treatment options might not put an end to dietary treatment but only alleviate its requirements. Therefore, the development of new and improvement of existing phenylalanine-free amino acid supplements and low protein products is mandatory. Irrespective of the preferred treatment, PKU remains a lifelong condition requiring medical care and attention with continuing research in different fields to provide individualized therapeutic strategies for our PKU patients.
5 5 References Blau, N., Hennermann, J. B., Langenbeck, U., & Lichter-Konecki, U. (2011). Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Molecular Genetics and Metabolism, 104 Suppl, S Danecka, M. K., Woidy, M., Zschocke, J., Feillet, F., Muntau, A. C., & Gersting, S. W. (2015). Mapping the functional landscape of frequent phenylalanine hydroxylase (PAH) genotypes promotes personalised medicine in phenylketonuria. Journal of Medical Genetics, 52(3), Ding, Z., Harding, C. O., Rebuffat, A., Elzaouk, L., Wolff, J. A., & Thöny, B. (2008). Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Molecular Therapy : The Journal of the American Society of Gene Therapy, 16(4), Etzel, M. R. (2004). Manufacture and use of dairy protein fractions. The Journal of Nutrition, 134(4), 996S 1002S. Retrieved from Fang, B., Eisensmith, R. C., Li, X. H., Finegold, M. J., Shedlovsky, A., Dove, W., & Woo, S. L. (1994). Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Therapy, 1(4), Retrieved from Feillet, F., & Agostoni, C. (2010). Nutritional issues in treating phenylketonuria. Journal of Inherited Metabolic Disease, 33(6), Gersting, S. W., Kemter, K. F., Staudigl, M., Lagler, F. B., Danecka, M. K., Messing, D. D., Muntau, A. (2007). Mutations in the PAH gene lead to protein misfolding with distinct alterations in oligomerization, enzyme kinetics, and protein stability. In Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (Vol. 30, p. 11).
6 6 Gersting, S. W., Lagler, F. B., Eichinger, A., Kemter, K. F., Danecka, M. K., Messing, D. D., Muntau, A. C. (2010). Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. Human Molecular Genetics, 19(10), Hamman, K., Clark, H., Montini, E., Al-Dhalimy, M., Grompe, M., Finegold, M., & Harding, C. O. (2005). Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria. Molecular Therapy : The Journal of the American Society of Gene Therapy, 12(2), Harding, C. O., & Blau, N. (2010). Advances and challenges in phenylketonuria. Journal of Inherited Metabolic Disease, 33(6), Harding, C. O., & Gibson, K. M. (2010). Therapeutic liver repopulation for phenylketonuria. Journal of Inherited Metabolic Disease, 33(6), Kure, S., Hou, D. C., Ohura, T., Iwamoto, H., Suzuki, S., Sugiyama, N., Narisawa, K. (1999). Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. The Journal of Pediatrics, 135(3), Retrieved from Laconi, E., & Laconi, S. (2002). Principles of hepatocyte repopulation. Seminars in Cell & Developmental Biology, 13(6), Retrieved from Lagler, F. B., Gersting, S. W., Zsifkovits, C., Steinbacher, A., Eichinger, A., Danecka, M. K., Muntau, A. C. (2010). New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Biochemical Pharmacology, 80(10), Lambruschini, N., Pérez-Dueñas, B., Vilaseca, M. A., Mas, A., Artuch, R., Gassió, R., Campistol, J. (2005). Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin
7 7 monotherapy. Molecular Genetics and Metabolism, 86 Suppl 1, S López-Villalobos, A., Lücker, J., López-Quiróz, A. A., Yeung, E. C., Palma, K., & Kermode, A. R. (2014). Preservation of high phenylalanine ammonia lyase activities in roots of Japanese Striped corn: a potential oral therapeutic to treat phenylketonuria. Cryobiology, 68(3), Matalon, R., Michals-Matalon, K., Bhatia, G., Grechanina, E., Novikov, P., McDonald, J. D., Guttler, F. (2006). Large neutral amino acids in the treatment of phenylketonuria (PKU). Journal of Inherited Metabolic Disease, 29(6), Muntau, A. C., Röschinger, W., Habich, M., Demmelmair, H., Hoffmann, B., Sommerhoff, C. P., & Roscher, A. A. (2002). Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. The New England Journal of Medicine, 347(26), Ney, D. M., Blank, R. D., & Hansen, K. E. (2014). Advances in the nutritional and pharmacological management of phenylketonuria. Current Opinion in Clinical Nutrition and Metabolic Care, 17(1), Sarkissian, C. N., Gámez, A., Wang, L., Charbonneau, M., Fitzpatrick, P., Lemontt, J. F., Scriver, C. R. (2008). Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proceedings of the National Academy of Sciences of the United States of America, 105(52), Solverson, P., Murali, S. G., Brinkman, A. S., Nelson, D. W., Clayton, M. K., Yen, C.-L. E., & Ney, D. M. (2012). Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria. American Journal of Physiology. Endocrinology and Metabolism, 302(7), E
8 8 Staudigl, M., Gersting, S. W., Danecka, M. K., Messing, D. D., Woidy, M., Pinkas, D., Muntau, A. C. (2011). The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response. Human Molecular Genetics, 20(13), Strisciuglio, P., & Concolino, D. (2014). New Strategies for the Treatment of Phenylketonuria (PKU). Metabolites, 4(4), Van Calcar, S. C., & Ney, D. M. (2012). Food products made with glycomacropeptide, a lowphenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria. Journal of the Academy of Nutrition and Dietetics, 112(8), Zschocke, J. (2003). Phenylketonuria mutations in Europe. Human Mutation, 21(4),
University of Zurich. Zurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2011 The interplay between genotype, metabolic state and cofactor treatment governs
More informationBiochemical Pharmacology
Biochemical Pharmacology 80 (2010) 1563 1571 Contents lists available at ScienceDirect Biochemical Pharmacology journal homepage: www.elsevier.com/locate/biochempharm New insights into tetrahydrobiopterin
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 101 (2010) 110 114 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Sapropterin therapy increases
More informationNot intended for UK based media. Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years of age
Your Contact News Release Bettina Frank Phone +49 6151 72-4660 Not intended for UK based media Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 99 (2010) S90 S95 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Future treatment strategies
More informationMerck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU Below 4 Years of Age
Your Contact News Release Gangolf Schrimpf +49 6151 72-9591 Investor Relations +49 6151 72-3321 July 20, 2015 Merck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU
More informationMolecular mechanisms of PAH function in response to phenylalanine and tetrahydrobiopterin binding: implications for clinical management
Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig-Maximilians-Universität München Molecular mechanisms of PAH function in response to phenylalanine and tetrahydrobiopterin
More informationExtended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: A pilot study
Molecular Genetics and Metabolism 86 (2005) S1 S5 www.elsevier.com/locate/ymgme Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: A pilot study Betina Fiege
More informationEfficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria
DOI 10.1007/s10545-012-9464-3 ORIGINAL ARTICLE Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria Oriane Leuret & Magalie Barth & Alice Kuster & Didier Eyer & Loïc
More informationQuantification of phenylalanine hydroxylase activity by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2012 Quantification of phenylalanine hydroxylase activity by isotope-dilution
More informationTherapeutic Programming of Synthetic Biotic Medicines
Therapeutic Programming of Synthetic Biotic Medicines Synthetic Biotic TM medicines to perform and deliver critical therapeutic functions to treat diseases throughout the body An Engineered E. coli Nissle
More informationLow Therapeutic Threshold for Hepatocyte Replacement in Murine Phenylketonuria
doi:10.1016/j.ymthe.2005.03.025 ARTICLE Low Therapeutic Threshold for Hepatocyte Replacement in Murine Phenylketonuria Kelly Hamman, 1 Heather Clark, 1 Eugenio Montini, 2 Muhsen Al-Dhalimy, 2 Markus Grompe,
More informationPHENYLKETONURIA. Debbie Galo
PHENYLKETONURIA Debbie Galo What it is PKU? 1934 Metabolic disorder (chromosome 12) Autosomal recessive Deficiency of enzyme Phenylalanine Hydroxylase (PAH) Cannot convert phenylalanine to tyrosine More
More information1 Cognitive, Psychological and Behavioral Assessment Based Evidence
1 Cognitive, Psychological and Behavioral Assessment Based Evidence Preface Current medical evidence has led experts on PKU to suspect that current therapy for PKU may leave individuals with an increased
More information2015 PKU Patient Survey Results. National PKU Alliance PO Box 501, Tomahawk, WI
2015 PKU Patient Survey Results National PKU Alliance PO Box 501, Tomahawk, WI 54487 www.npkua.org www.adultswithpku.org The NPKUA Patient Survey demonstrates that strict dietary therapy and treatment
More informationAmal Alamri. Phenylketonuria
Amal Alamri Phenylketonuria Norwegian doctor Asbjørn Følling (left) discovered phenylpyrouvica (later termed phenylketonuria) in 1934 upon discovering that ten mentally retarded patients had phenylpyruvic
More informationPhenylketonuria: translating research into novel therapies
Review Article Phenylketonuria: translating research into novel therapies Gladys Ho 1,2, John Christodoulou 1,2,3,4 1 Genetic Metabolic Disorders Research Unit; 2 Disciplines of Paediatrics and Child Health
More informationPegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line
May 2016 Horizon Scanning Research & Intelligence Centre Pegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line LAY SUMMARY This briefing is based on information
More informationPhenylketonuria: a review of current and future treatments
Editor s note: Rare Diseases Column is chaired by Dr. Zhanhe Wu from The Children s Hospital at Westmead, Australia, featuring articles related to rare diseases mostly genetic based, presented in early
More informationLong-term Follow-up and Outcome of Phenylketonuria Patients on Sapropterin: A Retrospective Study. abstract ARTICLE
ARTICLE Long-term Follow-up and Outcome of Phenylketonuria Patients on Sapropterin: A Retrospective Study AUTHORS: Stefanie Keil, MD, a,b Karen Anjema, MD, c Francjan J. van Spronsen, MD, PhD, c Nilo Lambruschini,
More informationUnderstanding Treatment Options for Phenylketonuria Webcast January 2011 Marie LeFrancois, Dt.P. John Mitchell, M.D. Anna Maiorino
Understanding Treatment Options for Phenylketonuria Webcast January 2011 Marie LeFrancois, Dt.P. John Mitchell, M.D. Anna Maiorino Please remember that the views expressed on Patient Power do not necessarily
More informationBritish Journal of Nutrition
(2011), 106, 175 182 q The Authors 2011 doi:10.1017/s0007114511000298 Review Article Adjusting diet with sapropterin in phenylketonuria: what factors should be considered? Anita MacDonald 1 *, Kirsten
More informationChapter 1: What is PKU?
Chapter 1: What is PKU? A Parent's Perspective "If our child with PKU had been our first instead of our third, or if we had wanted more children after we had her, we would have done so, even knowing the
More informationPKU, KUVAN, and Your Child Making smart choices for PKU treatment
PKU, KUVAN, and Your Child Making smart choices for PKU treatment An educational brochure brought to you by BioMarin Pharmaceutical Inc. + = Low Low- diet Indication KUVAN (sapropterin dihydrochloride)
More informationPhenylketonuria (PKU) the Biochemical Basis. Biol 405 Molecular Medicine
Phenylketonuria (PKU) the Biochemical Basis Biol 405 Molecular Medicine PKU a history In 1934 Følling identified a clinical condition - imbecillitas phenylpyruvica. Mental retardation associated with this
More informationSapropterin dihydrochloride treatment in Turkish hyperphenylalaninemic patients under age four
The Turkish Journal of Pediatrics 2015; 57: 213-218 Original Sapropterin dihydrochloride treatment in Turkish hyperphenylalaninemic patients under age four Özlem Ünal 1, Hülya Gökmen-Özel 2, Turgay Coşkun
More informationClinical Commissioning Policy: Sapropterin for Phenylketonuria (all ages) NHS England Reference: P
Clinical Commissioning Policy: Sapropterin for Phenylketonuria (all ages) NHS England Reference: 1713P 1 NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning
More informationTetrahydrobiopterin responsiveness in patients with phenylketonuria
Clinical Biochemistry 37 (2004) 1083 1090 Tetrahydrobiopterin responsiveness in patients with phenylketonuria Belén Pérez-Dueñas a, Maria Antonia Vilaseca b, *, Anna Mas c, Nilo Lambruschini d, Rafael
More informationPhenylketonuria Treatment s Impact on Physical Growth: A Spanish Retrospective Longitudinal Study
Case Report imedpub Journals http://wwwimedpub.com Journal of Rare Disorders: Diagnosis & Therapy DOI: 10.21767/2380-7245.100014 Abstract Phenylketonuria Treatment s Impact on Physical Growth: A Spanish
More informationNew Drug Evaluation: Pegvaliase-pqpz injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationTrends in Enzyme Therapy for Phenylketonuria
Trends in Enzyme Therapy for Phenylketonuria Woomi Kim, 1,2 Heidi Erlandsen, 3, * Sankar Surendran, 4 Raymond C. Stevens, 1 Alejandra Gamez, Kimberlee Michols-Matalon, Stephen K. Tyring, 5 and Reuben Matalon
More informationAnnual Conference. 34th. The Rendezvous Hotel Skipton, Yorkshire. Welcome to. Programme Information & Abstracts
Welcome to 34th Annual Conference 2007 Programme Information & Abstracts The Rendezvous Hotel Skipton, Yorkshire The National Society for Phenylketonuria (United Kingdom) Ltd. NSPKU, PO Box 26642, London
More informationPKU PKU. Phenylketonuria TEMPLE. Information for families following Information for families after a positive newborn screening
PKU Phenylketonuria PKU Information for families following newborn a positive screening newborn screening Information for families after a positive newborn screening Information for families after a positive
More informationThe neonatal tetrahydrobiopterin loading test in phenylketonuria: what is the predictive value?
Anjema et al. Orphanet Journal of Rare Diseases (2016) 11:10 DOI 10.1186/s13023-016-0394-2 RESEARCH Open Access The neonatal tetrahydrobiopterin loading test in phenylketonuria: what is the predictive
More informationLong-term treatment of phenylketonuria with a new medical food containing large neutral amino acids
OPEN European Journal of Clinical Nutrition (2017) 71, 51 55 www.nature.com/ejcn ORIGINAL ARTICLE Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids D Concolino
More informationGene Therapy (2006) 13, & 2006 Nature Publishing Group All rights reserved /06 $
(2006) 13, 457 462 & 2006 Nature Publishing Group All rights reserved 0969-7128/06 $30.00 www.nature.com/gt SHORT COMMUNICATION Complete correction of hyperphenylalaninemia following liver-directed, recombinant
More informationPhenylketonuria (PKU) is an inherited metabolic disorder involving a group of genetic mutations that reduce the ability
Tetrahydrobiopterin Therapy for Phenylketonuria in Infants and Young Children Barbara K. Burton, MD, Darius J. Adams, MD, Dorothy K. Grange, MD, John I. Malone, MD, Elaina Jurecki, MS, RD, Heather Bausell,
More informationThe New England Journal of Medicine TETRAHYDROBIOPTERIN AS AN ALTERNATIVE TREATMENT FOR MILD PHENYLKETONURIA
TETRAHYDROBIOPTERIN AS AN ALTERNATIVE TREATMENT FOR MILD PHENYLKETONURIA ANIA C. MUNTAU, M.D., WULF RÖSCHINGER, M.D., MATTHIAS HABICH, HANS DEMMELMAIR, PH.D., BJÖRN HOFFMANN, CHRISTIAN P. SOMMERHOFF, M.D.,
More informationAuthor's personal copy
Molecular Genetics and Metabolism 10 (2011) 116 121 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Molecular genetics and impact
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 106 (2012) 264 268 Contents lists available at SciVerse ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Positive effect
More informationINVESTIGATION THE PREVALENCE OF MUTATIONS IVS 10 AND R158Q IN A NUMBER OF IRANIAN PATIENTS WITH PKU
: 293-297 ISSN: 2277 4998 INVESTIGATION THE PREVALENCE OF MUTATIONS IVS 10 AND R158Q IN A NUMBER OF IRANIAN PATIENTS WITH PKU SHIRIN JAHANBAZI, FATEMEHKESHAVARZI* Department of Biology, Sanandaj Branch,
More informationPhenylketonuria: Optimizing Therapeutic Efficacy
Phenylketonuria: Optimizing Therapeutic Efficacy Expanded Reference List Abadie V, Berthelot J, Feillet F, et al. Management of phenylketonuria and hyperphenylalaninemia: the French guidelines. Arch Pediatr.
More informationUNCORRECTED PROOF ORIGINAL ARTICLE. Steven F Dobrowolski 1, K Borski 2, CE Ellingson 1, R Koch 3, HL Levy 4 and EW Naylor 5
(29), 5 & 29 The Japan Society of Human Genetics All rights reserved 434-56/9 $32. www.nature.com/jhg ORIGINAL ARTICLE A limited spectrum of phenylalanine hydroxylase mutations is observed in phenylketonuria
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 96 (2009) 158 163 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Minireview Optimizing the
More informationREVIEW. Ania C. Muntau & Søren W. Gersting
DOI 10.1007/s10545-010-9185-4 REVIEW Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism Ania
More informationThe What, Why and How of Large Neutral Amino Acids
The What, Why and How of Large Neutral Amino Acids Kathryn Moseley, MS, RD Assistant Professor of Pediatrics USC/Keck School of Medicine LAC+USC Medical Center December 5 th, 2017 The opinions reflected
More informationPhenylalanine Hydroxylase Misfolding and Pharmacological Chaperones
Send Orders of Reprints at reprints@benthamscience.net 2534 Current Topics in Medicinal Chemistry, 2012, 12, 2534-2545 Phenylalanine Hydroxylase Misfolding and Pharmacological Chaperones Jarl Underhaug,
More informationLAUNCH ISSUE SUMMER 2011 Advances and challenges in PKU
PKU ACADEMY NEWSLETTER ADVANCES & CHALLENGES IN PKU Meeting report from the 3rd European Phenylketonuria Group Symposium & Dietitians Workshop, Lisbon, Portugal, 24-26 March 2011. LAUNCH ISSUE SUMMER 2011
More informationIndication criteria for disease: Phenylketonuria (PKU) [PAH]
deutsche gesellschaft für humangenetik e.v. Indication Criteria for Genetic Testing Evaluation of validity and clinical utility german society of human genetics www.gfhev.de Indication criteria for disease:
More informationLong-term follow-up of patients with phenylketonuria treated with tetrahydrobiopterin: a seven years experience
Scala et al. Orphanet Journal of Rare Diseases (2015) 10:14 DOI 10.1186/s13023-015-0227-8 RESEARCH Open Access Long-term follow-up of patients with phenylketonuria treated with tetrahydrobiopterin: a seven
More informationChallenges and Pitfalls in the Management of Phenylketonuria
Challenges and Pitfalls in the Management of Phenylketonuria AUTHORS: François Feillet, MD, a Francjan J. van Spronsen, PhD, b Anita MacDonald, PhD, c Friedrich K. Trefz, MD, d Mübeccel Demirkol, MD, e
More informationMutational and phenotypical spectrum of phenylalanine hydroxylase deficiency in Denmark
Clin Genet 2016: 90: 247 251 Printed in Singapore. All rights reserved Short Report 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12692 Mutational and
More informationPKU, a genetic disease, illustrating the principle:
PKU, a genetic disease, illustrating the principle: DNA RNA Protein What happens when a job doesn t get done? I. PKU, illustrates the relevance of chemistry to human health. PKU stands for phenylketonuria.
More informationPrerequisites Amino acid synthesis and degradation pathways. Integration of amino acid metabolic pathways with carbohydrate metabolic pathways.
Case 30 Phenylketonuria Focus concept The characteristics of phenylalanine hydroxylase, the enzyme missing in persons afflicted with the genetic disorder phenylketonuria (PKU), are examined. Prerequisites
More informationPhenylketonuria Jonathan Baghdadi and Evan Marlin
Phenylketonuria Jonathan Baghdadi and Evan Marlin Hyperphenylalaninemia (HPA) was first connected to certain types of mental retardation in 1934 by Asjborn Folling. Just a few years later it was understood
More informationHyperphenylalaninemia (HPA) has been called the epitome
GENETEST REVIEW Genetics in Medicine John J. Mitchell, MD 1,2,3, Yannis J. Trakadis, MD 1, and Charles R. Scriver, MD 1,2 TABLE OF CONTENTS Classification schemes...698 Clinical description...698 Untreated
More informationRecent Studies of Phenylketonuria By: Jennifer Gastelum Dr. Koni Stone Copyright 2014
Recent Studies of Phenylketonuria By: Jennifer Gastelum Dr. Koni Stone Copyright 2014 Phenylketonuria (PKU) is an autosomal recessive genetic disorder that causes an accumulation of toxic metabolites in
More informationOriginal Articles. Pitfalls in the Management of Phenylketonuria in China LL YANG, HQ MAO, WF ZHANG, ZY ZHAO, RL YANG, XL ZHOU, XL HUANG, XW HUANG
HK J Paediatr (new series) 2012;17:143-147 Original Articles Pitfalls in the Management of Phenylketonuria in China LL YANG, HQ MAO, WF ZHANG, ZY ZHAO, RL YANG, XL ZHOU, XL HUANG, XW HUANG Abstract Key
More informationBEHAVIORAL ASSESMENT OF THE Pah enu2 MOUSE MODEL OF PHENYLKETONURIA PADMINI ASHOK KUMAR
BEHAVIORAL ASSESMENT OF THE Pah enu2 MOUSE MODEL OF PHENYLKETONURIA By PADMINI ASHOK KUMAR A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
More informationESPEN Congress Madrid 2018
ESPEN Congress Madrid 2018 Inborn Errors Of Metabolism Phenylketonuria A. Macdonald (UK) Approach to Dietary Management of PKU Conflicts of interest Anita MacDonald has received research funding and honoraria
More informationArtificial liver in PKU. Donna Santillan, PhD University of Iowa Hospitals & Clinics Department of Obstetrics & Gynecology
Artificial liver in PKU Donna Santillan, PhD University of Iowa Hospitals & Clinics Department of Obstetrics & Gynecology Discovery of PKU Discovery of PKU Discovered in 1934 by Dr. Asbjörn Fölling Egeland
More informationSummary. Syndromic versus Etiologic. Definitions. Why does it matter? ASD=autism
Summary It is becoming clear that multiple genes with complex interactions underlie autism spectrum (ASD). A small subset of people with ASD, however, actually suffer from rare single-gene Important to
More informationPKU, KUVAN, and You PKU treatment and support for adults and young adults
PKU, KUVAN, and You PKU treatment and support for adults and young adults An educational brochure brought to you by BioMarin Pharmaceutical Inc. Phe control it s a lifelong goal! Most young people with
More informationGlycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial 1,2
Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial 1,2 Denise M Ney, 3 * Bridget M Stroup, 3 Murray K Clayton, 4,5 Sangita G Murali, 3 Gregory M
More informationThe National Society for Phenylketonuria (United Kingdom) Ltd. The Child with PKU. Brenda Clark Professor Forester Cockburn Dr Linda Tyfield
The National Society for Phenylketonuria (United Kingdom) Ltd. The Child with PKU Brenda Clark Professor Forester Cockburn Dr Linda Tyfield Revised by Dr Andrew Morris Front cover illustration kindly provided
More informationA. We are constantly being tested (from birth). 1) Why? Test newborns to check for congenital health problems. 2) What does congenital mean?
M 109 Introduction I. PKU illustrates the relevance of chemistry to human health Why is chemistry important in human health? Ex.: PKU (phenylketonuria) ref. Matalon, KM Top lin Nutr 16(4):41-50 (2001)
More informationIn vitro expression analysis of R68G and R68S mutations in phenylalanine hydroxylase gene
Vol. 47 No. 2/2000 365 369 QUARTERLY In vitro expression analysis of R68G and R68S mutations in phenylalanine hydroxylase gene Cezary ekanowski 1, Belen Perez 2, Lourdes R. Desviat 2, Wojciech Wiszniewski
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: van Spronsen FJ, van Wegberg AMJ, Ahring K,
More informationAdult PKU. Important Information for You. Mead Johnson Metabolics
This booklet is intended by Mead Johnson to be provided to you by your healthcare professional as part of his or her care plan in the dietary management of PKU. Your healthcare professional is your primary
More informationThe molecular basis of phenylketonuria in Koreans
J Hum Genet (2004) 49:617 621 DOI 10.1007/s10038-004-0197-5 ORIGINAL ARTICLE Dong Hwan Lee Æ Soo Kyung Koo Æ Kwang-Soo Lee Young-Joo Yeon Æ Hyun-Jeong Oh Æ Sang-Wun Kim Sook-Jin Lee Æ Sung-Soo Kim Æ Jong-Eun
More informationRevision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kuvan) Reference Number: CP. PHAR.43 Effective Date: 02.01.10 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More information4. FJ van Spronsen, GM Enns. Future treatment strategies in phenylketonuria. Molecular Genetics and Metabolism 99 (2010): S90 S95.
References 1. National Institutes of Health Consensus Development Panel (2001) National Institutes of Health Consensus Development Conference Statement. Phenylketonuria (PKU): Screening and Management,
More informationMetabolic Disorders. Chapter Thomson - Wadsworth
Metabolic Disorders Chapter 28 1 Metabolic Disorders Inborn errors of metabolism group of diseases that affect a wide variety of metabolic processes; defective processing or transport of amino acids, fatty
More informationCheck the status of Haplotypes VNTR, MspI and PvuII (a) in the PAH gene in Tabriz population genotype data using Family Threesome
Bulletin of Environment, Pharmacology and Life Sciences Bull. Env.Pharmacol. Life Sci., Vol 4 [4] March 2015: 101-106 2014 Academy for Environment and Life Sciences, India Online ISSN 2277-1808 Journal
More informationA preliminary mutation analysis of phenylketonuria in southwest Iran
A preliminary mutation analysis of phenylketonuria in southwest Iran N. Ajami 1 *, S.R. Kazeminezhad 1 *, A.M. Foroughmand 1, M. Hasanpour 1 and M. Aminzadeh 2 1 Department of Genetics, Faculty of Science,
More informationPanel: Report of Scientific Advisory Board Research Advancements July 30, 8:15am-9:15am
Panel: Report of Scientific Advisory Board Research Advancements July 30, 8:15am-9:15am Dr. Cary Harding National PKU Alliance (NPKUA) July 28-31, 2016, Indianapolis, IN Disclosures Cary Harding has received
More informationPKU TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ DESIGNED AND ADAPTED BY THE DIETITIANS GROUP
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ Australasian Society for Inborn Errors of Metabolism DESIGNED AND ADAPTED BY THE DIETITIANS GROUP PKU British
More informationTaking you to a new dimension. Vitaflo s first GMP-based protein substitute.
Taking you to a new dimension. Vitaflo s first GMP-based protein substitute. What is a protein substitute and why do I need it? Proteins are made up of small building blocks called amino acids. As you
More informationPhenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?
Molecular Genetics and Metabolism 86 (2005) S22 S26 Minireview www.elsevier.com/locate/ymgme Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now? Christineh N.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Palynziq) Reference Number: CP.PHAR.140 Effective Date: 07.31.18 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
More informationNEUROCOGNITIVE, OUTCOMES IN PKU: IT S TIME TO RAISE THE BAR
NEUROCOGNITIVE, OUTCOMES IN : IT S TIME TO RAISE THE BAR KEY POINTS 1. High Phenylalanine (Phe) levels harm the brain.. Traditional therapies do not completely protect individuals with. 3. New approaches
More informationPathophysiology of the Phenylketonuria
Problem 4. Pathophysiology of the Phenylketonuria Readings for this problem are found on pages: 79-82, 84, 85-6, 945-6 and 1019 of your Pathophysiology (5 th edition) textbook. (This problem was based
More informationTetrahydrobiopterin responsiveness: results of the BH 4 loading test in 31 Spanish PKU patients and correlation with their genotype
Molecular Genetics and Metabolism 83 (2004) 157 162 www.elsevier.com/locate/ymgme Tetrahydrobiopterin responsiveness: results of the BH 4 loading test in 31 Spanish PKU patients and correlation with their
More informationCurrent Drug Targets, 2016, 17,
ISSN: 1389-4501 eissn: 1873-5592 Impact Factor: 3.021 SCIENCE BENTHAM Send Orders for Reprints to reprints@benthamscience.ae 1515 REVIEW ARTICLE Current Drug Targets, 2016, 17, 1515-1526 Pharmacological
More informationYOU ARE WHAT YOU EAT. What are some of the biggest nutritionrelated threats the world faces today?
YOU ARE WHAT YOU EAT What are some of the biggest nutritionrelated health threats the world faces today? In what way can we help people make sensible, sustainable choices? NUTRIENTS Nutrients are chemical
More informationThe stress of phenylalanine on rats to study the phenylketonuria at biochemical and molecular level
. Journal of Applied Pharmaceutical Science Vol. 4 (04), pp. 024-029, April, 2014 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2014.40405 ISSN 2231-3354 The stress of phenylalanine on
More informationPAH phenylalanine + oxidant tyrosine CH 2 +H 3 N
M 109 Introduction An essential pattern employed by all living things: DNA RNA Protein DNA is the information storage molecule. RNA is an intermediate in information flow. Proteins do most of the jobs
More informationDisclosure. I have no disclosures to mention
Disclosure I have no disclosures to mention Liberalization of the Dietary Restrictions for PKU Patients: Large Neutral Amino Acids (LNAA) Supplementation in PKU Mice Dr. Eddy A. van der Zee, University
More informationRecommendations for the nutrition management of phenylalanine hydroxylase deficiency
American College of Medical Genetics and Genomics Systematic Review Open Recommendations for the nutrition management of phenylalanine hydroxylase deficiency Rani H. Singh, PhD, RD 1, Fran Rohr, MS, RD
More information9 7) 843 (300) 888 (323) (257) 3 (240) 0001). 6 18/41 (44%) (95% CI
Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study Harvey
More informationChapter 9. Biotransformation
Chapter 9 Biotransformation Biotransformation The term biotransformation is the sum of all chemical processes of the body that modify endogenous or exogenous chemicals. Focus areas of toxicokinetics: Biotransformation
More informationMy PKU Binder. P.O. Box 501 Tomahawk, WI
My PKU Binder P.O. Box 501 Tomahawk, WI 54487 www.npkua.org PKU Handbook A Guide for PKU from Diagnosis to Adulthood Provided by the National PKU Alliance www.npkua.org Acknowledgements Based upon Australasian
More informationScreening for Phenylketonuria: A Literature Update for the U.S. Preventive Services Task Force
Screening for Phenylketonuria: A Literature Update for the U.S. Preventive Services Task Force Prepared by: Iris Mabry-Hernandez, MD, MPH Tracy Wolff, MD, MPH Kathy Green, MD, MPH Corresponding Author:
More informationThe phenylketonuria mouse model: a meeting review
Molecular Genetics and Metabolism 76 (2002) 256 261 Review The phenylketonuria mouse model: a meeting review J. David McDonald, a, * Maria Andriolo, b Francesco Calı, b Mario Mirisola, c Stefano Puglisi-Allegra,
More informationCommittee Approval Date: August 15, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru152 Topic: Kuvan, sapropterin Date of Origin: March 18, 2008 Committee Approval Date: August 15, 2014 Next Review Date: September 2015 Effective Date: October 1,
More informationHyperphenylalaninemia (HPA; Online Mendelian Inheritance in ManÒ database: ), which includes phenylketonuria (PKU) at the most severe
Functional and structural characterization of novel mutations and genotype phenotype correlation in 51 phenylalanine hydroxylase deficient families from Southern Italy Aurora Daniele 1,2,3, Iris Scala
More informationIdentification and functional analysis of. mutations of the phenylalanine. hydroxylase gene in patients with. phenylketonuria
Identification and functional analysis of mutations of the phenylalanine hydroxylase gene in patients with phenylketonuria Sang-Wun Kim Department of Medicine The Graduate School, Yonsei University Identification
More informationPsych 3102 Lecture 3. Mendelian Genetics
Psych 3102 Lecture 3 Mendelian Genetics Gregor Mendel 1822 1884, paper read 1865-66 Augustinian monk genotype alleles present at a locus can we identify this? phenotype expressed trait/characteristic can
More information